Arvinas Inc (ARVN)

Nov 11, 2026

Zacks Research has downgraded Arvinas (NASDAQ:ARVN) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains "Moderate Buy" with a target price of $15.18. The company's recent quarterly earnings reported a beat on EPS at -$0.82 but significantly missed revenue expectations at $0.50 million, a 98.8% year-over-year decrease. Despite the downgrade, shares were up 2.4% on the day, opening at $6.92.

Nov 11, 2026

Arvinas, Inc. (Nasdaq: ARVN) announced its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is a clinical-stage biotechnology firm focused on targeted protein degradation to develop new drugs. A live audio webcast of the presentation will be available for interested parties.

Nov 3, 2026

Arvinas reported its Q3 2026 financial results, showcasing $558.9 million in cash and equivalents and a projected cash runway into the second half of 2028. The company is advancing several clinical trials, including ARV393 for lymphoma and ARV027 for spinal bulbar muscular atrophy, with key data readouts anticipated in 2027. Management emphasized data-driven capital allocation and plans to initiate a Phase 1b trial for ARV102 in Europe and the UK for neurodegenerative diseases.

Nov 3, 2026

Arvinas, Inc. has filed a Form S-3 shelf registration statement with the SEC, allowing for a potential securities offering of up to $400 million. This total includes a specific $200 million at-the-market (ATM) common stock facility. Piper Sandler & Co. and Cantor Fitzgerald & Co. are named as agents for the ATM sales, with the registration pending effectiveness at the time of filing.